Dacarbazine

Dacarbazine is a nonspecific antineoplastic (antineoplastic) alkylating agent. Dacarbazine inhibits T and B lymphocyte responses with IC50 of 50 and 10 μg/mL, respectively. Dacarbazine can be used in the study of metastatic malignant melanoma[1][2][3][4][5].

Product Specifications

CAS Number

[4342-03-4]

Product Name Alternative

Imidazole Carboxamide

UNSPSC

12352005

Hazard Statement

H302, H312, H315, H319, H332, H335, H350, H360

Target

Apoptosis; Nucleoside Antimetabolite/Analog

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Dacarbazine.html

Purity

99.96

Solubility

0.1 M HCl : 20 mg/mL (ultrasonic; warming; heat to 60°C) |DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL

Smiles

O=C(C1=C(/N=N/N(C)C)NC=N1)N

Molecular Formula

C6H10N6O

Molecular Weight

182.18

Precautions

H302, H312, H315, H319, H332, H335, H350, H360

References & Citations

[1]Serrone, L., et al., Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res, 2000. 19 (1) : p. 21-34.|[2]Al-Badr AA, et al. Dacarbazine. Profiles Drug Subst Excip Relat Methodol. 2016;41:323-77.|[3]Rojo JM, et al. Inhibition of T and B lymphoblastic response by mithramycin, dacarbazine, prospidium chloride and peptichemio. Chemotherapy. 1983;29 (5) :345-51.|[4]Erdmann S, et al. Induced cross-resistance of BRAFV600E melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment. Sci Rep. 2019 Jan 10;9 (1) :30.|[5]Salvador D, et al. Combined Therapy with Dacarbazine and Hyperthermia Induces Cytotoxicity in A375 and MNT-1 Melanoma Cells. Int J Mol Sci. 2022 Mar 25;23 (7) :3586.